Group items tagged

Fat injections are a non-surgical and non-invasive way that help you in achieving the desired contours and appearance. The procedure involve transfer of fat tissues from one part of body that has excess fat deposits to the area that needs volume which improves the definition of both body areas simultaneously.

This lipedema liposuction under this method involves injection into the affected areas with large volumes of epinephrine and dilute lidocaine into the subcutaneous fat. Lidocaine is a local anesthetic while epinephrine is a drug which makes capillaries shrink.

Cheek implant surgery aims at improving the appearance of sunken cheeks that have lost their shape and volume by placing implants in them,while Chin augmentation surgery is the right option for you if you have recessed chin and you want to improve its appearance. The procedure involves insertion of implant in chin.

A transport wheelchair is a mobility chair designed for convenience, short-distance use and easy handling by a caregiver. Lightweight and foldable, these wheelchairs are easily moved and typically fit in the trunk of most vehicles. There is even a model designed to fold into a bag to be carried over the shoulder. Transport Chair is designed to create a welcoming and safe environment that speaks volumes to caregivers, patients and their family members. Obvious touchpoints help make operation intuitive for all users. BackSmart ergonomics have been incorporated into the design to reduce the bending and reaching associated with caregiver injury. A rigid frame helps enhance durability while reducing the risk of theft. This investment in the well-being of patients and caregivers tells them care about their comfort and safety. Transport wheel chairs are practical for errands and trips to the store or the doctor. Hospitals sometimes utilize these flexible mobility chairs to move patients around their facilities. Karma KM 2500 L Big Wheel Wheelchair: Karma KM 2500 L Wheelchair Specifications: Width 18" Front/Rear Wheels 6" to 22" Seat Width 47cm Seat Depth 40cm Overall Width 66cm Overall Collapsed Width 36cm Armrest Height 21cm Overall Length 90cm Seat Height 47cm Backrest Height 38cm Overall Height 86cm Weight 11.kg Karma KM 2500 L Wheelchair Seat and Back: AEGIS Microbe Shield Approved by the FDA, EPA, EU, etc., bonded anti-microbial barrier upholstery protects from odor, staining and deterioration from bacteria, fungus and other microorganisms. It is a shield for your health. Karma KM 2500 L Wheelchair Extended Armrest By simulating the natural position of arms, the extended armrest design is ergonomic and creates bigger seating space. An Ultra lightweight wheelchair (11 kg) with a compact design for either attendant assisted or self propelling users. The use of aircraft-grade aluminium alloy and double cross brace provide this

Brand new and high quality hearing aid sound amplifier Super mini size and light weight, not easily to be seen Adjust volume to the minimum before wearing

Rose is aptly called as the masterpiece of all flowers as they have a strong personality of their own and are able to bring out positive and happy feelings in people. The beauty of a rose mesmerizes people and leaves a lasting impression in their hearts. There are around 24 color varieties of rose and each color symbolizes specific emotions associated with it. There are more than 150 species of roses and hybrids with varied shapes. Roses tend to grow more vigorously in the greenhouse than in open farms and can flower up to three times a year. Undisturbed by wind and rain, the leaves can be clean and healthy and the blooms perfect. The average growing temperature and the temperature strategy influences the growth, development of roses, and burning of sawdust during winter months in the early morning increases the yield. Growers following the greenhouse environmental conditions can use specific models to adjust the production time so as to be able to meet specific demand periods. Depending on the species and varieties, roses may be used as cut flowers, and used in making rose oil, rose water, perfumes, cosmetics, and gulkhand sweet. Measured in terms of volume of trade in the international market cut roses rank first in popularity. Production of cut roses in greenhouses has been increasing over the last few years due to availability of advanced environmental control possibility and demand from overseas markets. The overall profitability of a rose greenhouse farm depends upon the quality of roses produced and best returns are obtained when the fresh roses are air shipped to foreign markets to be used in perfumeries and cosmetics industries.

The conjugate release pad can perform multiple tasks, the most important of which is uniform transfer of the detector reagent and test sample onto the membrane. The most important function of the conjugate pad is to deliver the detector particles onto the membrane in a consistent volume of sample on every test strip.

This full body shaper will firmly shape and give you the compression you need after lipo, tummy tuck or any plastic surgery procedure. This is a Stage 2 Post op Faja Enjoy top to bottom slimming in this full body girdle, This comfortable braless girlde gives you a slim and smooth silhouette for anytime you wan to look your best or after post surgical procedure. Plus is adds a plus it enhances your buttocks with a silk comfortable built in butt enhancer. Cold firming lycra material inside with high compression powernet long -leg girdle helps smooth your figure while adding everyday comfort, Slimming your thighs and helping compress bulges and help your legs look leaner. This body shaping compression garment has a zipper down the middle for easy adjusting with hooks on the inside with open crotch area for easy bathroom use. This is the second stage girdle you will need after any surgery it covers all areas and gives you maximum compression. RESULTS Full-body slimming enhances your silhouette Appearance of firmer, smoother midsection Smooths and slim your legs Adds volume and shape to your booty

In its effort to address workforce challenges, Health Education and Improvement Wales has outlined initiatives aimed at facilitating the return of pharmacy professionals with refugee status to active practice within Wales. This possibility has been stated in HEIW's Strategic Pharmacy Workforce Plan, which commits to investigating the practicality and significance of establishing a registration pathway for pharmacy professionals displaced due to refugee status. According to HEIW, it is currently investigating the viability and importance of revitalising 'return to practice' packages, formulating pharmacy apprenticeships, initiating international recruitment initiatives, and establishing a registration pathway in Wales for displaced pharmacists and pharmacy technicians holding refugee status. "In the past two years, we have arrived at a point where maintaining the desired access to the volume and quality of pharmacy services for our population has proven unattainable," said HEIW. "In Wales, instances of diminished pharmacy services are evident in both hospital and community settings. The trend of abrupt, temporary closures in community pharmacies continues."

The price concession for Atorvastatin 80mg has been increased to £3.91 from the previously set £3.45 for prescriptions dispensed in July, the Community Pharmacy England has said. The Department of Health and Social Care additionally introduced a concession price of £3.38 for Atorvastatin 20mg. "In July, our Dispensing and Supply Team experienced an unusually high influx of reports from pharmacies struggling to acquire Atorvastatin 80mg tablets at the listed Drug Tariff price," said CPE. CPE requested a price concession early in the month. However, after extended discussions, an agreement on the price wasn't reached. Consequently, on July 31st, the DHSC imposed a concession of £3.45. Addressing enduring pharmacy concerns over the pricing, CPE intensified advocacy with DHSC. This endeavour resulted in the revision of the Atorvastatin 80mg tablet concession price to £3.91 for prescriptions submitted and dispensed in July. According to CPE, this adjusted price sufficiently covers costs as reported by the majority of pharmacy owners. However, DHSC has refrained from modifying concessionary prices for the other two requested lines by CPE. DHSC communicated that their team's data collection for July, employing real-time sales and volume data, was incongruent with the adjustment of these prices, CPE further said.

To help pharmacy owner to better understand the negotiating process, Community Pharmacy England (CPE) has published commentary and infographics. "Our work to negotiate fair funding, as well as changes to NHS pharmacy services, with the Department of Health and Social Care (DHSC) and NHS England is a crucial part of our role," said CPE. "Understandably the sector is eagerly awaiting an update on the progress of the current negotiations on the Government's pledge to invest £645m in community pharmacies and, as part of our ongoing efforts to improve transparency of our work, we have released materials to explain the negotiating process." Negotiating Team Member Stephen Thomas - who joined the team this year - has written a blog about his experiences. He has described both the complexity of the process and volume of work undertaken, and recognises the significance of his role on behalf of pharmacy owners across the country. Whilst speed is of the essence, even higher on the Negotiating Team's list of priorities is working through a large number of important questions - particularly around the funding and logistics that need to be put in place.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

A winter NHS crisis is inevitable unless the government acts now to reverse the worrying decline in community pharmacies. Years of government underfunding could see 3,000 pharmacies in England - around a third of the network - having no option but to shut their doors to patients in the next few years. That figure is based on independent assessments from Ernst & Young and UCL/LSE healthcare professors: it is not scaremongering - it is the reality the country faces. Fifty per cent of pharmacies are already in financial distress because government funding has been falling in real terms since 2019 and that figure is predicted to rise to 75 per cent within the next two years. The government needs to act now and invest in pharmacy or sleepwalk into a healthcare disaster as we have seen with access to dentistry care. Prescription volumes have risen consistently year-on-year by roughly 2 per cent which means fewer pharmacies doing more work and under greater pressure than a decade ago. Ten years ago around 11,200 pharmacies in England were dispensing roughly 79,000 prescriptions; nowadays around 11,500 are dispensing roughly 89,000 prescriptions. The secretary of state recently asked pharmacy to do more to avoid a winter NHS crisis and at the same time said there will be no new money to pay for those additional services. This at a time when the network is in decline with random unplanned pharmacy closures - 640 closures since 2016 - and pharmacy staff face huge workload pressures as prescription demand is increasing year-on-year. The government's approach to pharmacy literally does not add up: the pharmacy contract is not fit-for-purpose now let alone dealing with a NHS winter crisis.

Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value. The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of January 18, 2023, the last trading day prior to today's announcement. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which is in late-stage development. It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.

HRA Pharma is celebrating the 1st anniversary of Hana, the first type of daily oral contraception available in the UK without a prescription. The launch of Hana in 2021 followed the historic decision of the Medicines and Healthcare products Regulatory Agency (MHRA) to grant a marketing authorisation and marked a significant step forward in the women's contraception category. The company reports that pharmacists have embraced the reclassification and have found merit in using emergency contraception consultations as an opportunity to educate women on their over-the-counter contraception options. Alison Slingsby, innovations project manager at HRA Pharma, commented: "We have been delighted with Hana's reception - within weeks of launch, it quickly became the best-selling mini-pill without prescription, with more than 95 per cent market share, and has maintained this market leading position ever since. We previously had the experience of switching emergency contraceptive ellaOne to a P medicine, Hana is on track to match and eventually exceed the ellaOne volumes.

Within the last few weeks, at least six pharmacists have been subjected to interim order applications - either suspended or had significant restrictions placed upon their registration pending a full 'Fitness to Practise' hearing into serious allegations being made about their prescribing practices, the Pharmacists' Defence Association (PDA) has found. It said that there has been a "dramatic increase in action being taken by the pharmacy regulator (GPhC) against pharmacist prescribers associated with certain types of online prescribing services". It has warned pharmacist prescribers who work for online pharmacies about the specific risks associated with remote prescribing using a questionnaire-based model, typically with no direct prescriber/patient interaction. Common features that underpin the allegations include the following: Overreliance on a patient questionnaire to inform clinical decision making; No patient/prescriber interaction; Prescribing high risk medicines without adequate safeguards; Inadequate systems and processes leading to inappropriate prescribing; Very high volumes of prescriptions being authorised in short periods of time; and Prescribers/patient relationship established via an unregulated online portal.

The Department of Health and Social Care (DHSC) announced that free COVID-19 lateral flow tests will be supplied through community pharmacies for at-risk groups. The service will operate from 6 November for patients aged over 12 years who are at risk of developing severe COVID-19 symptoms. Community pharmacies that have participated in this new initiative will be paid £4 plus VAT for each box of five lateral flow device test kits provided. Alastair Buxton, Director of NHS services at Community Pharmacy England said: "This is not going to be a high-volume service, but community pharmacy teams are well placed to provide LFD test kits to eligible patients with them having made over 25.5 million supplies of COVID-19 LFD test kits in 2021/22.

Keith Ridge, who retired from the role of England's chief pharmaceutical officer this month, has written to the NHS regional directors regarding a package to empower community pharmacies to implement clinical services in their integrated care systems. Though details about this letter are not available, Malcolm Harrison, chief executive officer of the Company Chemists' Association, welcomed the move saying: "It is a positive step towards the greater integration of community pharmacy care into the NHS. "It is vital for the NHS that patients can benefit from the clinical care services set out in the Community Pharmacy Contractual Framework." Harrison, however, highlighted that while pharmacies are being pushed to do more, the efforts to introduce new clinical services should be supported with "sustainable funding and material actions to increase workforce numbers in the sector." "We are concerned that without the funding and people in place, the desired volume of necessary services cannot be delivered, no matter how well coordinated."

DE Group, one of the UK's leading independent pharmaceutical wholesalers, has gone into administration. Pharmacy Business has learnt that the group was put into administration on Monday (May 9), putting hundreds of jobs at risk and stoking fears of a "sudden shock" to pharmaceutical supply chain. A community pharmacy contractor who has done business with the wholesaler for over 20 years told Pharmacy Business: "I fear for the worst. I don't think there will be enough supply of medicines to cope up with a surge at such a short notice." Bharat Shah, founder and CEO of Sigma Pharmaceuticals, another leading short-line wholesaler, said the news will send shock-waves and have "a massive impact on the market" because DE Group enjoyed a "substantial coverage and market share" in the independent pharmacy sector. "It won't be easy for anyone to take on the extra volume as it could jeopardise their own business," he said, adding that Sigma was actively looking into expanding its own operations in the foreseeable future.

It's no secret that as pharmacists we are navigating a new and more demanding healthcare landscape. Our role has changed significantly since the start of the 21st century due to increased expectations from the public, advances in science and technology and changing workforce pressures. The Community Pharmacy Contractual Framework for England has placed a higher focus on clinical service. In addition, the Covid-19 pandemic resulted in significant acceleration in changing how we work day-to-day and the public perception of our role. Community pharmacy owners and staff have been under relentless pressure for the last two years. Dispensing volumes are continually increasing but dispensing revenues are being replaced by launching new services. We must find solutions to reduce the time it takes to dispense medication so we can focus on these new revenue generating services. To not just succeed, but to thrive, it is becoming increasingly important to understand and embrace the technology available.